Ebola Outbreak: Democratic Republic of the Congo

Debate between Lord Patel and Baroness Goldie

Monday 20th May 2019 Lords Chamber

[Baroness Goldie]

I thank the noble Lord for raising that very important point. There is of course concern about not just the virulence of this disease but the facility with which it can spread. There is always a question to be raised over both spread within the country itself and international spread. I should make it clear that, as I understand it, although no cases have spread beyond the North Kivu and Ituri provinces, the WHO assesses the risk for the regional spread of Ebola as very high, especially given the instability and violence. The UK is the largest donor to preparedness activities, through the WHO regional plan and bilaterally, but it is critical that other international partners step up. DfID staff are working with the WHO, the OCHA, host Governments and other partners to implement measures to robustly prepare for potential spread. The noble Lord makes an important point, and it is an issue that will, I think, be assessed very carefully on a regular basis.

[Lord Patel (CB)]

My Lords, as mentioned, this is a serious and dangerous situation. It is dangerous because the number of cases has risen over the past six months, which shows our inability to control or contain the spread of this disease. Of the 1,600 cases reported, 1,100 people have died. Currently, 15 to 20 new cases are occurring every day. We know how to control the spread of this virus and we have learned from the previous outbreak. What we cannot do this time is get health workers in to provide the necessary strategy required to contain the spread of the virus and provide vaccinations. That cannot happen until the warring factions—and there are several of them—stop fighting. We should be working on international arrangements to control the fighting and create a ceasefire: unless we have a ceasefire, we will not be able to contain the spread of this disease. Does the Minister agree?

My second question is this: what is the stock of the vaccinations available? Are we going to run out of vaccines?

[Baroness Goldie]

If I may, I will respond to the latter point first. I understand that there is availability of vaccines; as to what the stock is, I do not have an answer, but I will endeavour to find out and will respond to the noble Lord.

The noble Lord makes a very important point in relation to the particular elements of this disaster—and it is a disaster—which make addressing it so challenging and difficult. It is correct that there is a need to address community conflict and issues of suspicion, distrust and violence, and activity by hostile and disparate groups, which is, as he rightly identifies, prejudicing the ability to deal with the disease itself.

We also have to recognise that there are delicate cultural and national issues within the Democratic Republic of the Congo. That is why, echoing the points made by the noble Lord, Lord Collins, and the noble Baroness, Lady Northover, I think it is very important that, in conjunction with the Government of the Democratic Republic of the Congo, we consider how best we can help them deal with these issues. We want to be very careful that there is no question of trying to impose solutions or be seen to be interfering when such is not our intention.

The noble Lord makes an important point, and it is something of which the UK Government are acutely aware. That is one reason there is a desire for the forthcoming ministerial visit to North Kivu. Following that visit, it will be possible to make a further assessment as to what we can do—either ourselves, bilaterally with the DRC, or in conjunction with our global partners in the World Health Organization and the United Nations—to more constructively address the important issue he has identified.

European Union (Withdrawal) Bill

Debate between Lord Patel and Baroness Goldie

Committee: 6th sitting (Hansard): House of Lords
Monday 12th March 2018 Lords Chamber

[Baroness Goldie]

I am not in any way diminishing the important point that the noble Lord makes. I am pointing out that there are many types of clinical trials—for example, at the moment we are engaged in partnerships with non-EU countries. However, the Prime Minister has made it clear that we desire to have the closest possible relationship with the EU. We think that the systems we have been engaged in around clinical trials have been very strong, good and important.

[Lord Patel]

My Lords, it was not my intention to intervene. I am sorry to do so but it has been forced upon me. I think there is a fundamental failure of understanding here. Clinical trials are planned over a long time: it takes at least six to eight months to plan a clinical trial; it takes a lot of collaboration to find out whether we will be able to recruit the same category of patients; and we are required to understand whether the people who volunteer to join the trial have the necessary patience to do so. Because of this time lag, my amendment seeks to raise a very simple question. We had agreed to a regulation—the new clinical trials regulation—and we believed that it would come into force this year and therefore would be incorporated into the current European Union (Withdrawal) Bill. By a quirk of fate, that will not happen. But we have already agreed to have it in the Bill, so, as the noble Lord, Lord Forsyth, said, what is the problem with incorporating it in the Bill?

[Baroness Goldie]

The problem is that the Bill is intended to transfer a body of law from A to B. At the moment, this regulation is incomplete: it has not been enacted and it is not currently in the body of EU law. That is why there is a risk that it will not be covered under this Bill.

--- Later in debate ---

[Baroness Goldie]

I must apologise to the noble and learned Lord; the Chief Whip sat down and bumped into me, so I was distracted from hearing what he had to say. I certainly offer to come back to that point.

[Lord Patel]

My Lords, it is difficult for me to sum up. The message is quite clear to me, although that might merely be perception, that my friend, the noble Baroness, Lady Goldie, is in some difficulty. It is quite clear to all those who understand the amendment—and, more importantly, the European trials regulation and the law as specified in the Bill—that there is no reason why we cannot incorporate this into the Bill.

The noble Lord, Lord Warner, suggested that we might need to bring another amendment; I suppose he means with the view to having a vote. That was not my intention when I tabled the amendment. It was merely to clarify the Government’s position on importing the European trials regulation into the Bill as we are the prime movers of the regulation and we are formulating it. The solution identified by the noble and learned Lord, Lord Mackay of Clashfern, seems to be the answer to cover all such regulations that we might have agreed to and might come into force. This is not the first time that he has come to my rescue. He has done so twice before, on admixed embryos and on mental health having equal esteem. Both times they were put to the vote and the votes were won—so that is a warning.

I hope the Minister might agree that more work needs to be done on this by Ministers. I am glad to understand that the noble Lord, Lord Callanan, is to meet with Cancer Research UK and others at some stage in March, I assume to discuss this and other science issues. I hope he will agree that there might be a place for the Ministers to meet and see whether there is a solution. Otherwise, I fear that either there will be an amendment in the form suggested by the noble and learned Lord, Lord Mackay, or, if it is not me, somebody else will table an amendment. We can tell from the support this amendment received even from strong Brexiteers such as the noble Lords, Lord Lawson and Lord Forsyth, and the noble Viscount, Lord Ridley, that such an amendment might be carried.